Please assess the completion status of the following clinical trial:

Trial Title: ATTIC - Access To Treat in the Community

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants 18 years or older with chronic hepatitis C genotype 1 or 4 will be eligible.~2. Able and wiling to provide written informed consent.~3. Both interferon treatment naïve and experienced participants will be included.~4. Participants without cirrhosis will be eligible if HCV RNA positive, documented chronic hepatitis C and a FibroScan of ≤ 12.5.~5. Participants with cirrhosis (Fibroscan \> 12.5 or APRI \> 2) will be eligible if the serum albumin is \> 3.5 g/dl, platelets \> 100,000 and INR \< 1.5 and there is no prior history of hepatic decompensation.~6. Participants with well controlled HIV coinfection will be included, but should be stabilized on antiretrovirals for which no clinically significant interaction is expected.~7. Participants who are HBsAg positive will be included, but will require antiviral prophylaxis for HepB. Anti- HbC positive participants will be included. Prophylaxis will not be given, but these participants will require careful monitoring of their ALT levels.~Exclusion Criteria:~* Persons with prior HCV DAA treatment~* Individuals younger than 18 years of age~* Individuals infected with genotypes other than 1a or 1b or 4 HCV identified on screening; however such participants identified on screening will be offered appropriate NHS England standard of treatment for the genotype.~* Unable or unwilling to give informed consent~* Active tuberculosis~* Females who are pregnant, planning pregnancy or breastfeeding~* Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within three months of study enrolment~* Clinically-significant medical or psychiatric illness (other than chronic HCV) in the past, present, or being evaluated, that may interfere with participant treatment, safety, assessment or compliance with the protocol~* Participants with cirrhosis (Fibroscan \> 12.5 or APRI \> 2) and serum albumin is \< 3.5 g/dl, platelets \<100,000 and INR \> 1.5 or a prior history of hepatic decompensation~* Severe renal impairment with eGFR \<30 mL/min/1.73m2 or requiring dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: OTHER): A phase 4, open label, non-randomised study, conducted in hostels and homeless shelters in London; as well as mobile clinics in collaboration with the Hep C trust and the NHS Find and Treat program.~Treatment: 12 or 16 weeks of Zepatier, based on genotypes; with Ribavarin for certain subtypes. The study drug is administered as a single tablet; which is a combination of 100 mg of grazoprevir and 50 mg of elbasvir; as outlined below:~Genotypes 1a/b and 4: once daily dose for 12 weeks, taken with / without food. Genotype 1a and 4: (HCV RNA\> 800,000 iu/ml or baseline NS5A resistance): once daily dose for 16 weeks, taken with / without food.~NO dose modifications with the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).